Adjuvant pazopanib does not PROTECT against recurrence of high-risk, initially localized renal cell cancer but does provide novel insights

Grant D. Stewart, Bradley C. Leibovich, Sylvie Negrier, Robert A. Figlin

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)3995-3997
Number of pages3
JournalJournal of Clinical Oncology
Issue number35
StatePublished - Dec 10 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this